Company / Operating Income
AVADEL PHARMACEUTICALS PLC Operating Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$42.4M
FY2024
5-year range
-$137.8M / $5.8M
FY2020-FY2024
Trend
+69.2%
vs FY2023
Sector context
#70 of 204
Health Care
What the data says
At -$42M, AVADEL PHARMACEUTICALS PLC's operating income ranks #70 of 204 in the Health Care sector. Operating Income returned to growth in FY2024 after 3 years of decline, reaching -$42M.
Based on SEC 10-K filings.
-$42M in FY2024.
Improved from -$99M to -$42M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#70 of 204 in Health CareTop 34% of 204This company -$42.4M Sector average $107.7M
▼
-139.4% below sector average
Key checks
Key Insights
- In FY2024, operating income increased 69.2% year-over-year.
- Ranks #70 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$42.4M | +69.2% |
| FY2023 | -$137.8M | -39.9% |
| FY2022 | -$98.6M | -15.2% |
| FY2021 | -$85.5M | -1571.1% |
| FY2020 | $5.8M | +124.1% |
| FY2019 | -$24.1M | +77.0% |
| FY2018 | -$104.9M | -217.2% |
| FY2017 | $89.5M | +1902.7% |
| FY2016 | -$5.0M | -107.0% |
| FY2015 | $70.8M | +175.6% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026